Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Metastasis Review

• Publication date

  2008-01-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10555-008-9119-xPMID 18213449
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

  2008influential reference
• CIP2A inhibits PP2A in human malignancies.

  2007influential reference
• FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

  2007influential reference
• Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.

  2007influential reference
• The PP2A inhibitor SET regulates natural killer cell IFN- (cid:4) production

  2007cited by this paper
• A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain

  2007cited by this paper
• A Conserved Pathway That Controls c-Myc Protein Stability through Opposing Phosphorylation Events Occurs in Yeast*

  2007cited by this paper
• Selection of Protein Phosphatase 2A Regulatory Subunits Is Mediated by the C Terminus of the Catalytic Subunit*

  2007cited by this paper
• From mRNA Metabolism to Cancer Therapy: Chronic Myelogenous Leukemia Shows the Way

  2007cited by this paper
• The PP2A inhibitor SET regulates natural killer cell IFN-γ production

  2007cited by this paper
• The tumor suppressor PP2A Abeta regulates the RalA GTPase.

  2007cited by this paper
• Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation

  2006cited by this paper
• ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia

  2006cited by this paper
• Identification of a tumour suppressor network opposing nuclear Akt function

  2006cited by this paper
• The glycine 90 to aspartate alteration in the Aβ subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function

  2006cited by this paper
• Regulation of cell adhesion by PP2A and SV40 small tumor antigen: An important link to cell transformation

  2006cited by this paper
• Protein tyrosine phosphatases: from genes, to function, to disease

  2006cited by this paper
• Protein Phosphatase 2A Regulatory Subunit B56α Associates with c-Myc and Negatively Regulates c-Myc Accumulation

  2006cited by this paper
• Structure of the protein phosphatase 2A holoenzyme.

  2006cited by this paper
• Fingolimod. Mitsubishi Pharma/Novartis.

  2005cited by this paper
• Developing therapeutics for the treatment of multiple sclerosis

  2005cited by this paper
• Involvement of PP2A in viral and cellular transformation

  2005cited by this paper
• Induction of Drug Metabolism by Forskolin: The Role of the Pregnane X Receptor and the Protein Kinase A Signal Transduction Pathway

  2005cited by this paper
• The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

  2005influential reference
• FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure‐Response Relationship

  2005cited by this paper
• FLT3/ITD Mutation Signaling Includes Suppression of SHP-1*

  2005cited by this paper
• Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity.

  2005cited by this paper
• PP2A: the expected tumor suppressor.

  2005cited by this paper
• Ral GTPases: corrupting the exocyst in cancer cells.

  2005cited by this paper
• The Life Cycle of C-Myc: From Synthesis to Degradation

  2004cited by this paper
• Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects

  2004cited by this paper
• Identification of specific PP2A complexes involved in human cell transformation.

  2004cited by this paper
• FTY720: mechanism of action and potential benefit in organ transplantation.

  2004cited by this paper
• PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.

  2004cited by this paper
• Review Principles of Tumor Suppression Erties of " Classic " Tumor Suppressor Genes. First, They

  2004cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

  2004cited by this paper
• Protein Kinases and Phosphatases: The Yin and Yang of Protein Phosphorylation and Signaling Review

  2004cited by this paper
• A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression.

  2003cited by this paper
• The function of the protein tyrosine phosphatase SHP-1 in cancer.

  2003cited by this paper
• Protein Phosphatase 2A Dephosphorylation of Phosphoserine 112 Plays the Gatekeeper Role for BAD-Mediated Apoptosis

  2003cited by this paper
• Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question.

  2003cited by this paper
• Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage.

  2003cited by this paper
• A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells

  2003cited by this paper
• SHP‐1 suppresses cancer cell growth by promoting degradation of JAK kinases

  2003cited by this paper
• A novel cAMP-stimulated pathway in protein phosphatase 2A activation.

  2002cited by this paper
• B56-Associated Protein Phosphatase 2A Is Required For Survival and Protects from Apoptosis in Drosophila melanogaster

  2002cited by this paper
• hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis

  2002cited by this paper
• Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer

  2002cited by this paper
• Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits

  2002cited by this paper
• Cyclin G recruits PP2A to dephosphorylate Mdm2.

  2002cited by this paper
• Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta.

  2002influential reference
• First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.

  2002cited by this paper
• Protein Phosphatase 2A Interacts with and Directly Dephosphorylates RelA*

  2001cited by this paper
• Oncogenes and cell proliferation

  2001cited by this paper
• Protein phosphatase 2A: the Trojan Horse of cellular signaling.

  2001cited by this paper
• Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene

  2001cited by this paper
• Mitogenic and nutritional signals are transduced into translational efficiency of TOP mRNAs.

  2001cited by this paper
• Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus

  2001cited by this paper
• PPP2R1B Gene in Chronic Lymphocytic Leukemias and Mantle Cell Lymphomas

  2001cited by this paper
• Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

  2001influential reference
• Involvement of Protein Phosphatase 2A in the Interleukin-3-Stimulated Jak2-Stat5 Signaling Pathway

  2001cited by this paper
• A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region

  2001cited by this paper
• Protein phosphatase 2A: variety of forms and diversity of functions.

  2001cited by this paper
• Role of serine/threonine protein phosphatase 2A in cancer.

  2001cited by this paper
• Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.

  2000cited by this paper
• A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation

  2000cited by this paper
• Modulation of Akt kinase activity by binding to Hsp90.

  2000cited by this paper
• Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers

  2000cited by this paper
• Tumor progression and metastasis.

  2000cited by this paper
• The Hallmarks of Cancer Review

  2000cited by this paper
• Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms

  2000cited by this paper
• BCR/ABL inhibition by an escort/phosphatase fusion protein.

  2000cited by this paper
• Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

  1999cited by this paper
• Oncogenes.

  1999cited by this paper
• Identification by differential display of a protein phosphatase‐2A regulatory subunit preferentially expressed in malignant melanoma cells

  1999cited by this paper
• Functional interaction between a novel protein phosphatase 2A regulatory subunit, PR59, and the retinoblastoma-related p107 protein

  1999cited by this paper
• Drosophila S6 kinase: a regulator of cell size.

  1999cited by this paper
• Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase

  1998cited by this paper
• I1PP2A and I2PP2A. Two potent protein phosphatase 2A-specific inhibitor proteins.

  1998cited by this paper
• Alterations of the PPP2R1B gene in human lung and colon cancer.

  1998cited by this paper
• HRX Leukemic Fusion Proteins Form a Heterocomplex with the Leukemia-associated Protein SET and Protein Phosphatase 2A*

  1997cited by this paper
• 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.

  1997cited by this paper
• The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

  1997influential reference
• The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A (*)

  1996cited by this paper
• Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.

  1995cited by this paper
• Oncogenes and cell proliferation.

  1995cited by this paper
• Oncogenes and cell proliferation.

  1995cited by this paper
• Inhibition of cdc2 activation by INH/PP2A.

  1994cited by this paper
• Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.

  1994cited by this paper
• The 55 kd regulatory subunit of Drosophila protein phosphatase 2A is required for anaphase.

  1993cited by this paper
• The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation.

  1993cited by this paper
• Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

  1992cited by this paper
• CDC55, a Saccharomyces cerevisiae gene involved in cellular morphogenesis: identification, characterization, and homology to the B subunit of mammalian type 2A protein phosphatase

  1991cited by this paper
• Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases

  1991cited by this paper
• Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics.

  1988cited by this paper
• Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein.

  1981cited by this paper

• CaMKK as a Potential Target for the Natural Product Insecticide Cytisine against Megoura japonica Matsumura.

  2025cites this paper
• Protein phosphatase 2A regulates blood cell proliferation and differentiation in Drosophila larval lymph glands

  2024cites this paper
• Identification of a survival associated gene trio in chemical induced breast cancer.

  2023cites this paper
• Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.

  2023cites this paper
• Okadaic Acid Inhibits Protein Phosphatases to Suppress Spermatogonial Cell Proliferation

  2022cites this paper
• Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients

  2022cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• A phosphatase‐centric mechanism drives stress signaling response

  2021cites this paper
• Serine/Threonine Phosphatases in Osteoclastogenesis and Bone Resorption.

  2020cites this paper
• Correcting abnormalities in miR-124/PTPN1 signaling rescues tau pathology in Alzheimer's disease.

  2020cites this paper
• Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer’s Disease

  2020cites this paper
• FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.

  2019cites this paper
• γ-Tocotrienol-Inhibited Cell Proliferation of Human Gastric Cancer by Regulation of Nuclear Factor-κB Activity.

  2019cites this paper
• The Therapeutic Potential of the Labdane Diterpenoid Forskolin

  2019cites this paper
• The Therapeutic Potential of the Labdane

  2019cites this paper
• Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back

  2018cites this paper
• Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer

  2018cites this paper
• Protein phosphatase 2A as therapeutic targets in various disease models

  2018cites this paper
• Transcriptional and Behavioral Responses of Zebrafish Larvae to Microcystin-LR Exposure

  2017cites this paper
• Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells

  2017cites this paper
• Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.

  2017cites this paper
• Cyanobacterial Toxins of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in Drinking Water

  2017cites this paper
• Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion

  2017cites this paper
• FTY720-derivatives do not induce FTY720-like lymphopenia

  2017cites this paper
• Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation.

  2017cites this paper
• High CFTR expression in philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A

  2017cites this paper
• Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

  2017cites this paper
• OP449 inhibits breast cancer growth without adverse metabolic effects.

  2017influential citation
• Signalling by protein and drug development: a systems-centred view

  2017cites this paper
• Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products.

  2016cites this paper
• Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest

  2016cites this paper
• Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia

  2016cites this paper
• Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy

  2016cites this paper
• Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?

  2016cites this paper
• A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia

  2016cites this paper
• Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options

  2016cites this paper
• 1 PP 2 A phosphatase suppresses function of the mesenchymal invasion regulator NEDD 9

  2016cites this paper
• The emerging role of FTY720 (Fingolimod) in cancer treatment

  2016cites this paper
• The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance

  2016cites this paper
• Design, synthesis and biochemical characterization of Fingolimod analogs for targeting PP2A

  2016cites this paper
• HDAC1 controls CIP2A transcription in human colorectal cancer cells

  2016cites this paper
• Enhancing the Power of Endogenous Protein Phosphatase 2A to Combat Asthmatic Inflammation: Role for MAPKs and Tristetraprolin

  2016influential citation
• Tyrosine Kinase Inhibitors and Phosphatases: Overcoming the BCR-ABL T315I Mutation in CML with a Synergistic Combination of Ponatinib and Forskolin

  2016cites this paper
• The Interplay between PP2A and microRNAs in Leukemia

  2015cites this paper
• Raf/MEK/ERK Signaling

  2015cites this paper
• PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

  2015influential citation
• Tristetraprolin and Its Role in Regulation of Airway Inflammation

  2015cites this paper
• From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies

  2015cites this paper
• Role of Sphingolipids in Hematological Malignancies: Myeloproliferative Disorders

  2015cites this paper
• Methamphetamine-induced sensitization is associated with alterations to the proteome of the prefrontal cortex: implications for the maintenance of psychotic disorders.

  2015cites this paper
• Use of p 38 MAPK Inhibitors To Repress Inflammatory Disease : What Have We Learned ?

  2015cites this paper
• Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

  2014cites this paper
• F-box Protein FBXL16 Binds PP2A-B55α and Regulates Differentiation of Embryonic Stem Cells along the FLK1+ Lineage*

  2014cites this paper
• Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer

  2014cites this paper
• Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.

  2014cites this paper
• The Basic Biology of PP2A in Hematologic Cells and Malignancies

  2014cites this paper
• Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.

  2014cites this paper
• Cancer Biology and Signal Transduction PP 2 A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY 720 Shows Promising Therapeutic Potential

  2014cites this paper
• Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.

  2014cites this paper
• Toward the stereoselective synthesis of C1–C23 fragment of spirastrellolide B

  2014cites this paper
• F-box Protein FBXL16 Binds PP2A-B55 and Regulates Differentiation of Embryonic Stem Cells along the FLK1 Lineage*□S

  2014cites this paper
• Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome

  2013cites this paper
• Novel therapies for treatment of Ph+ acute leukemias

  2013cites this paper
• PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis

  2013cites this paper
• Antagonistic activities of the immunomodulator and protein phosphatase 2A (PP2A)-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven myeloproliferative neoplasms.

  2013cites this paper
• Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

  2013cites this paper
• S100A8/A9 (Calprotectin) Negatively Regulates G2/M Cell Cycle Progression and Growth of Squamous Cell Carcinoma

  2013cites this paper
• MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol

  2013cites this paper
• Structure, regulation, and pharmacological modulation of PP2A phosphatases.

  2013cites this paper
• Functional Genetic Polymorphisms in PP2A Subunit Genes Confer Increased Risks of Lung Cancer in Southern and Eastern Chinese

  2013cites this paper
• Interdiction of sphingolipid metabolism to improve standard cancer therapies.

  2013influential citation
• Induction of a Feed Forward Pro-Apoptotic Mechanistic Loop by Nitric Oxide in a Human Breast Cancer Model

  2013cites this paper
• Ready, set? Go! Microscopy and image analysis of cell signalling in cell migration

  2013cites this paper
• Protein phosphatase 2A: a target for anticancer therapy.

  2013cites this paper
• Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A.

  2013cites this paper
• Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment

  2013cites this paper
• Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

  2013cites this paper
• New perspectives on molecular targeted therapy in ovarian clear cell carcinoma

  2013cites this paper
• Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway

  2013cites this paper
• Designing Tools to Probe the Calcium-dependent Function of Arabidopsis Tonneau2

  2013cites this paper
• Cellular inhibitors of Protein Phosphatase PP2A in cancer.

  2012cites this paper
• Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.

  2012cites this paper
• Development of a phosphoprotein enrichment method to identify and characterize phosphoproteins within leukemia following treatment with the PP2A activator, FTY720

  2012cites this paper
• Nitric oxide and protein phosphatase 2 A provide novel therapeutic opportunities in ER-negative breast cancer

  2012cites this paper
• Where are we going with CML research?

  2012cites this paper
• Signalling by protein phosphatases and drug development: a systems‐centred view

  2012cites this paper
• PP-1α and PP-1γ display antagonism and differential roles in tumorigenicity of lung cancer cells.

  2012cites this paper
• Molecular targets of FTY720 (fingolimod).

  2012cites this paper
• Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response

  2012cites this paper
• The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.

  2012cites this paper
• PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9.

  2012cites this paper
• Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways

  2012cites this paper
• The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells.

  2012cites this paper
• Sphingolipid metabolism and leukemia: a potential for novel therapeutic approaches.

  2011cites this paper
• The biology of chronic myelogenous leukemia progression: who, what, where, and why?

  2011cites this paper
• Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

  2011cites this paper
• The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues

  2011cites this paper
• Human Cancer-Associated Mutations in the Aα Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in Aα Knock-In and Knockout Mice

  2011cites this paper
• Bioactive sphingolipids in response to chemotherapy: a scope on leukemias.

  2011cites this paper
• Regulatory roles of calprotectin in head and neck squamous cell carcinogenesis.

  2011cites this paper